News

Sorting Cancers by ‘Immune Archetypes’ May Offer New Approach For Precision Immunotherapies

UCSF Researchers Uncover Common Immune Microenvironments Across Different Types of Cancer MORE

QSant, the first urine test for kidney transplant rejection, Featured at Biotech Showcase Digital 2022

NephroSant, a biotechnology company launched on University of California, San Francisco technology, and dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, announced that it will present a company overview at the upcoming Biotech Showcase conference...

See With Your Ears

Scott Harris, a UCSF Neuroscience PhD Candidate, Brings Home The Blackstone LanchPad Prize

Global Blood Therapeutics granted FDA label expansion for sickle cell disease therapy

Global Blood Therapeutics is trading higher after the FDA expanded the approval for the company’s sickle cell disease therapy Oxbryta (voxelotor), allowing its use in children as young as four years of age. Oxbryta, discovered by Matthew Jacobson, chair of the Department of Pharmaceutical Chemistry...

Neuvivo Launches to Develop Effective Treatments for ALS

Neuvivo, Inc., a company developing clinical-stage treatments for ALS and other neurodegenerative diseases based on the University of California, San Francisco lab discoveries by co-founder Michael McGrath, today announced its corporate launch, the expansion of its executive team, and the creation...

Exai Bio Launches Big in Series A Financing

Exai Bio, a next-generation liquid biopsy company based on the University of California, San Francisco’s technologies for early cancer detection developed in Dr.

Neurona Therapeutics to Present New Data for Lead Neural Cell Therapy Program

Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology. A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been...

The Truth About Innovation

OTMA Executive Director Anthony Francis opens up about MedTech innovation and using the academic institution as a launchpad for startups. MORE

Chroma Medicine Launches with $125M

Chroma Medicine, a NewCo based on UCSF technologies to advance programmable epigenetic editors that harness innate mechanisms to precisely control gene ex

Neurona Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy in Epilepsy Patients

Neurona Therapeutics, a biotherapeutics company founded in UCSF technology to advance restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has received clearance of its Investigational New Drug (IND) application f